Epigenetic changes in osteosarcoma

Bulletin du Cancer

Volumn 98, Issue 7, 2011, Pages

  Cui, Juncheng ^a   Wang, Wanchun ^a   Li, Zhihong ^a   Zhang, Zhaogui ^a   Wu, Bei ^b   Zeng, Li ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

DNA methylation; Epigenetics; Histone modifications; Osteosarcoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTISENSE OLIGONUCLEOTIDE; AZACITIDINE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; DOXORUBICIN; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; PROCAINAMIDE; PROCAINE; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RECQ HELICASE; ROMIDEPSIN; SOMATOMEDIN B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

APOPTOSIS; BONE MARROW SUPPRESSION; BREAST TUMOR; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CELL CYCLE; CELL PROLIFERATION; CHROMATIN STRUCTURE; CPG ISLAND; CYTOSTASIS; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INDUCTION; EPIGENETICS; EPIPHYSEAL CARTILAGE; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HISTONE MODIFICATION; HUMAN; MELANOMA; MYELOID LEUKEMIA; OSTEOSARCOMA; PREVALENCE; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; RADIOSENSITIZATION; REVIEW; SINGLE DRUG DOSE; SOMNOLENCE; SUPPRESSOR GENE;

EID: 79960513692     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1400     Document Type: Review

References (78)

1. Marcove RC, Heelan RT, Huvos AG, Healey J, Lindeque BG. Osteoid osteoma. Diagnosis, localization, and treatment. Clin Orthop Relat Res 1991 ; 267 : 197-201.
2. Grimer RJ, Taminiau AM, Cannon SR. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br 2002 ; 84 : 395-400. (Pubitemid 34413771)
3. Wolffe AP. Epigenetics: regulation through repression. Science 1999 ; 286 : 481-6.
4. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999 ; 99 : 247-57. (Pubitemid 29519904)
5. Herman JG, Baylin SB. DNA hypermethylation in tumorigenesis epigenetics joins genetics. Trends Genet 2006 ; 16 : 168-74.
6. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987 ; 196 : 261-82. (Pubitemid 17122132)
7. Riggs AD, Pfeifer GP. X-chromosome inactivation and cell memory. Trends Genet 1992 ; 8 : 169-74.
8. Razin A, Cedar H. DNA methylation and genomic imprinting. Cell 1994 ; 77 : 473-6. (Pubitemid 24153986)
9. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006 ; 6 : 107-16. (Pubitemid 43361543)
10. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007 ; 8 : 286-98. (Pubitemid 46439286)
11. Warnecke PM, Bestor TH. Cytosine methylation and human cancer. Curr Opin Oncol 2000 ; 12 : 68-73. (Pubitemid 32046841)
12. Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr Relat Cancer 2001 ; 8 : 115-27. (Pubitemid 32641353)
13. Muthusamy V, Duraisamy S, Bradbury CM, et al. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 2006 ; 66 : 11187-93. (Pubitemid 46009946)
14. Wei G, Lonardo F, Ueda T, et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 1999 ; 80 : 199-204. (Pubitemid 29001722)
15. Aoyama T, Okamoto T, Nagayama S, et al. Methylation in the core-promoter region of the chondromodulin-I gene determines the cell-specific expression by regulating the binding of transcriptional activator Sp3. J Biol Chem 2004 ; 279 : 28789-97. (Pubitemid 38900164)
16. Villagra A, Gutierrez J, Paredes R, et al. Reduced CpG methylation is associated with transcriptional activation of the bone-specific rat osteocalcin gene in osteoblasts. J Cell Biochem 2002 ; 85 : 112-22. (Pubitemid 34204074)
17. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002 ; 94 : 1397-404. (Pubitemid 34212632)
18. Montero AJ, Diaz-Montero CM, Mao L, et al. Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer Biol Ther 2006 ; 5 : 1494-501.
19. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997 ; 7 : 871-5. (Pubitemid 27346731)
20. Al-Romaih K, Somers GR, Bayani J, et al. Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: identification of apoptotic genes as targets for demethylation. Cancer Cell Int 2007 ; 7 : 14.
21. Takai D, Jones PA. The CpG island searcher: a new WWW resource. In Silico Biol 2003 ; 3 : 235-40. (Pubitemid 37493047)
22. Al-Romaih K, Sadikovic B, Yoshimoto M, Wang Y, Zielenska M, Squire JA. Decitabine-induced demethylation of 5′ CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia 2008 ; 10 : 471-80. (Pubitemid 351657389)
23. Li Y, Meng G, Huang L, Guo QN. Hypomethylation of the P3 promoter is associated with up-regulation of IGF2 expression in human osteosarcoma. Hum Pathol 2009 ; 40 : 1441-7.
24. Savage SA, Woodson K, Walk E, et al. Analysis of genes critical for growth regulation identifies insulin-like growth factor 2 receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev 2007 ; 16 : 1667-74. (Pubitemid 47294836)
25. Esteller M, Tortola S, Toyota M, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000 ; 60 : 129-33. (Pubitemid 30058742)
26. Sarbia M, Geddert H, Klump B, Kiel S, Iskender E, Gabbert HE. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer 2004 ; 111 : 224-8. (Pubitemid 38924699)
27. Badal V, Menendez S, Coomber D, Lane DP. Regulation of the p14ARF promoter by DNA methylation. Cell Cycle 2008 ; 7 : 112-9.
28. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 1996 ; 86 : 136-42. (Pubitemid 26074804)
29. Hu N, Huang J, Emmert-Buck MR, et al. Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China. Clin Cancer Res 2001 ; 7 : 883-91. (Pubitemid 32708725)
30. Pogribny IP, James SJ. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation. Cancer Lett 2002 ; 176 : 169-74. (Pubitemid 34136016)
31. Lim S, Yang MH, Park JH, et al. Inactivation of the RASSF1A in osteosarcoma. Oncol Rep 2003 ; 10 : 897-901.
32. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002 ; 21 : 4345-9. (Pubitemid 34753843)
33. Nishijo K, Nakayama T, Aoyama T, et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer 2004 ; 111 : 367-72. (Pubitemid 38998816)
34. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst 2003 ; 95 : 669-74. (Pubitemid 36603723)
35. Young DW, Hassan MQ, Pratap J, et al. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 2007 ; 445 : 442-6. (Pubitemid 46160913)
36. Young DW, Hassan MQ, Yang XQ, et al. Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proc Natl Acad Sci U S A 2007 ; 104 : 3189-94. (Pubitemid 46364135)
37. Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther 2010 ; 9 : 731-41.
38. Urnov FD. Methylation and the genome: the power of a small amendment. J Nutr 2002 ; 132 : 2450S-6S.
39. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature 1999 ; 397 : 579-83.
40. Dunn BK. Hypomethylation: one side of a larger picture. Ann N Y Acad Sci 2003 ; 983 : 28-42. (Pubitemid 36399318)
41. Papaggeli PC, Kortsaris AC, Matsouka PT. Aberrant methylation of c-myc and c-fos protooncogenes and p53 tumor suppressor gene in myelodysplastic syndromes and acute non-lymphocytic leukemia. J BUON 2003 ; 8 : 341-50. (Pubitemid 38660086)
42. Wu JX, Carpenter PM, Gresens C, et al. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 1990 ; 5 : 989-1000.
43. Li Y, Meng G, Guo QN. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol 2008 ; 84 : 234-9.
44. Al-Kuraya K, Novotny H, Bavi P, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007 ; 60 : 768-72. (Pubitemid 47056905)
45. Bhattacharya N, Sabbir MG, Roy A, Dam A, Roychoudhury S, Panda CK. Approximately 580 Kb surrounding the MYC gene is amplified in head and neck squamous cell carcinoma of Indian patients. Pathol Res Pract 2005 ; 201 : 691-7. (Pubitemid 41487598)
46. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, Huvos AG. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 1993 ; 2 : 163-7. (Pubitemid 23252434)
47. Schübeler D, MacAlpine DM, Scalzo D, et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 2004 ; 18 : 1263-71. (Pubitemid 38720594)
48. Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem 2006 ; 75 : 243-69. (Pubitemid 44118033)
49. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003 ; 983 : 84-100. (Pubitemid 36399322)
50. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005 ; 2 : 150-7. (Pubitemid 40823166)
51. Sowa Y, Orita T, Minamikawa S, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997 ; 241 : 142-50. (Pubitemid 28033553)
52. Liao WM, Zhang CL, Li FB, Zeng BF, Zeng YX. p21WAF1/CIP1 gene DNA sequencing and its expression in human osteosarcoma. Chin Med J (Engl) 2004 ; 117 : 936-40.
53. Maeda T, Nagaoka Y, Kawai Y, et al. Inhibitory effects of cancer cell proliferation by novel histone deacetylase inhibitors involve p21/WAF1 induction and G2/M arrest. Biol Pharm Bull 2005 ; 28 : 849-53. (Pubitemid 40740654)
54. Watanabe K, Okamoto K, Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 2005 ; 12 : 10-8. (Pubitemid 40090024)
55. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002 ; 16 : 6-21. (Pubitemid 34049633)
56. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002 ; 3 : 415-28. (Pubitemid 34587077)
57. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002 ; 62 : 7213-8. (Pubitemid 36025241)
58. Antequera F, Bird A. CpG islands as genomic footprints of promoters that are associated with replication origins. Curr Biol 1999 ; 9 : R661-667.
59. Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 2001 ; 20 : 2536-44. (Pubitemid 32452872)
60. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000 ; 25 : 338-42. (Pubitemid 30437325)
61. Cheng MF, Lee CH, Hsia KT, Huang GS, Lee HS. Methylation of histone H3 lysine 27 associated with apoptosis in osteosarcoma cells induced by staurosporine. Histol Histopathol 2009 ; 24 : 1105-11.
62. Hiraki Y, Tanaka H, Inoue H, Kondo J, Kamizono A, Suzuki F. Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytes. Biochem Biophys Res Commun 1991 ; 175 : 971-7.
63. Aoyama T, Okamoto T, Kohno Y, et al. Cell-specific epigenetic regulation of ChM-I gene expression: crosstalk between DNA methylation and histone acetylation. Biochem Biophys Res Commun 2008 ; 365 : 124-30. (Pubitemid 350102462)
64. Toh Y, Pencil SD, Nicolson GL. A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem 1994 ; 269 : 22958-63.
65. Park HR, Cabrini RL, Araujo ES, Paparella ML, Brandizzi D, Park YK. Expression of ezrin and metastatic tumor antigen in osteosarcomas of the jaw. Tumori 2009 ; 95 : 81-6.
66. Kiss NB, Geli J, Lundberg F, et al. Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extraadrenal paragangliomas but not pheochromocytomas. Endocr Relat Cancer 2008 ; 15 : 609-21. (Pubitemid 351880847)
67. Maitra A, Roberts H, Weinberg AG, Geradts J. Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. Int J Cancer 2001 ; 95 : 34-8.
68. Christman JK. 5-azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002 ; 21 : 5483-95. (Pubitemid 34983483)
69. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002 ; 321 : 591-9. (Pubitemid 36124798)
70. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailabi -lity of azacitidine subcutaneous versus intravenous in patients with themyelodysplastic syndromes. J Clin Pharmacol 2005 ; 45 : 597-602. (Pubitemid 40562951)
71. Cheng JC, Weisenberger DJ, Gonzales FA, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004 ; 24 : 1270-8. (Pubitemid 38112188)
72. Wittenburg LA, Bisson L, Rose BJ, Korch C, Thamm DH. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol 2010 ; 67 : 83-92.
73. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007 ; 25 : 84-90. (Pubitemid 46087907)
74. Kisseberth WC, Murahari S, London CA, Kulp SK, Chen CS. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. Am J Vet Res 2008 ; 69 : 938-45.
75. Blattmann C, Oertel S, Ehemann V, et al. Enhancement of radiation response in osteosarcoma and rhabomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2010 ; 78 : 237-45.
76. Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002 ; 11 : 1695-713. (Pubitemid 35469917)
77. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999 ; 21 : 103-7. (Pubitemid 29036293)
78. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007 ; 318 : 1108-13. (Pubitemid 350134889)